I
Ivabradine
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
Medical Assistance Fund
Active ingredient: Ivabradine
General information
Subsidy Information and Financing Scheme
[MAF] Ivabradine Tablet 5 mg, 7.5 mg
Treatment of chronic heart failure in patients with New York Heart Association (NYHA) class II to IV stable chronic heart failure with systolic dysfunction (LVEF of 35% or less), and who are in sinus rhythm with a heart rate of 75 bpm or more, and who are given concomitant standard medical management including the maximum tolerated dose of beta-blocker therapy, angiotensin converting enzyme inhibitors and aldosterone antagonists, unless contraindicated or not tolerated
Drug Guidance for Subsidy
05/02/2018 Ivabradine for the treatment of chronic stable angina and chronic heart failure
The Ministry of Health's Drug Advisory Committee has recommended:
Ivabradine 5mg and 7.5mg tablets for the treatment of chronic heart failure in patients:
with New York Heart Association (NYHA) class II to IV stable chronic heart failure with systolic dysfunction (LVEF of 35% or less);
who are in sinus rhythm with a heart rate of 75 bpm or more and
who are given concomitant standard medical management with maximum tolerated doses of beta blockers, angiotensin-converting enzyme inhibitors and aldosterone antagonists, unless contraindicated.
Subsidy status
[R] Ivabradine 5mg and 7.5mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.
[NR] MAF assistance does not apply to the use of ivabradine for chronic stable angina.
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Tablet 5 mg |
|
Tablet 7.5 mg |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.